DermBiont, Inc.

Venture capital mega-rounds of $100m or more – like the $245m series A round that Aiolos Bio Inc. announced on 24 October – have played a big part in surging quarterly and annual totals of biopharma

Big backing for venture capital-funded private biopharmaceutical companies has not wavered as 2021 draws to a close despite a recent slowdown in large initial public offerings by drug developers in th